Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care products gorilla Johnson & Johnson (JNJ 0.22%) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at J&J and see what CAPS investors are saying about the stock right now.
J&J facts
|
Headquarters (founded) |
New Brunswick, N.J. (1886) |
|
Market Cap |
$205.6 billion |
|
Industry |
Pharmaceuticals |
|
Trailing-12-Month Revenue |
$67.2 billion |
|
Management |
Chairman/CEO Alex Gorsky |
|
Return on Equity (average, past 3 years) |
19.8% |
|
Cash/Debt |
$19.8 billion / $16.9 billion |
|
Dividend Yield |
3.3% |
|
Competitors |
Covidien |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 14,045 members who have rated J&J believe the stock will outperform the S&P 500 going forward.
Just yesterday, one of those Fools, brenoboyle, succinctly summed up J&J bull case for our community:
[J&J] has had some nice quarterly reports recently, looks undervalued by cash flow and seems to be in the midst of a successful turnaround. They are controlling costs and leveraging the firm's comparative advantage.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
